Successful completion of Initial Public Offering and listing on Bombay Stock Exchange and National Stock Exchange on February 4, 2025

AGARWAL’S HEALTH CARE LIMITED

Revenue from Operations soars by 29.5% YoY to INR 431 Crores

EBITDA grows by 26.3% YoY to INR 128 Crores

PAT grows by 25.0% YoY to INR 28 Crores

Mumbai, February 17, 2025: Dr. Agarwal’s Health Care Limited (NSE: AGARWALEYE, BSE: 544350), India’s largest eye care service chain⁽¹⁾ operating a network of 221 Facilities across 10 countries, today announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2024.

Highlights of the Quarter Ended December 31, 2024 (Q3 FY2025)

• Revenue from Operations of INR 431 Cr, growth of 29.5% YoY
  • Revenue from Operations – India of INR 390 Cr, growth of 34.5% YoY
  • Revenue from Mature Facilities of INR 291 Cr, growth of 16.6% YoY
• EBITDA of INR 128 Cr, growth of 26.3% YoY with EBITDA margin of 28.8%
• Profit after Tax of INR 28 Cr, growth of 25.0% YoY with PAT margin of 6.4%
• 221 Facilities as of December 31, 2024
  • 12 Facilities have been added in Q3 FY2025

Highlights for the Nine Months Ended December 31, 2024 (9M FY2025)

• Revenue from Operations of INR 1,251 Cr; growth of 27.2% YoY
  • Revenue from Operations – India of INR 1,124 Cr, growth of 31.7% YoY
  • Revenue from Mature Facilities of INR 874 Cr, growth of 15% YoY
• Sale of Services⁽²⁾ contributed 79.9% and Sale of Products⁽²⁾ contributed 20.1% to revenue from operations
• EBITDA of INR 356 Cr, growth of 27.5% YoY with EBITDA margins of 27.8%
• Profit after Tax of INR 68 Cr, growth of 26.2% YoY with profit after tax margins of 5.3%
• 42 Facilities were added in 9M FY2025
  • Of these 35 new Facilities have been set up and seven Facilities have been acquired
• Performed 213,602 surgeries in 9M FY2025, growth of 31.8% YoY

Commenting on Q3 FY2025 and Nine Months ended December 31, 2024 results, Dr. Adil Agarwal, CEO, Dr. Agarwal’s Health Care Limited, said:

“We are delighted to announce our maiden quarter performance post listing where we have delivered a robust growth of 29.5% in revenue and 26.3% in EBITDA. We have continued to witness strong growth in both patient footfalls and the number of surgeries performed. Our commitment to providing exceptional care, along with investments in cutting-edge technology, positions us for long-term success. While we have maintained our growth trajectory, we remain committed to delivering sustainable and steady growth in the coming quarters.”

Financial Highlights:

1. By revenue from operations for FY24
2. Services include Surgeries, Consultation, Treatments and Investigations; Products include Opticals, Contact Lens and Accessories, and Pharmaceutical Products

About Dr. Agarwal’s Health Care Limited:

Dr. Agarwal’s Health Care Limited, a trusted brand in the eye care services industry and according to the CRISIL MI&A Report dated January 2025 is India’s largest eye care service chain by revenue from operations for FY2024. With long-standing operational history, we endeavour to address all the needs of our patients in their eye treatment journey through a network of 205 Facilities across 14 states and 4 UT in India and 16 Facilities across nine countries in Africa. The Company has a diversified presence, with 73 facilities located in Tier-I cities and 132 facilities in other cities across India.

We provide end-to-end comprehensive eye care services, including cataract, refractive and other surgeries; consultations, diagnoses and non-surgical treatments; and sells opticals, contact lenses and accessories, and eye care related pharmaceutical products. Our business operations are structured as a “hub and spoke” model, which enables us to build a scalable and accessible platform for the continued growth of our business. Our integrated hub-and-spoke model enables deeper geographic penetration, allowing greater accessibility to patients while driving efficiency of critical resources across the network.

Safe Harbour Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.